These 10 Firms Soared Last Week, Here’s Why

2. Hims & Hers Health, Inc. (NYSE:HIMS)

Hims & Hers jumped by 45.3 percent week-on-week to end at $40.82 on Friday, versus the $28.09 the week prior, as news that it clinched a long-term partnership with Novo Nordisk sparked buying appetite while investors repositioned portfolios ahead of its first quarter earnings performance.

According to the company, it will announce its earnings results after the market closes on Monday, May 5, 2025, where investors will be closely watching out for its updated outlook guidance for the rest of the year.

In recent news, Hims & Hers Health, Inc. (NYSE:HIMS) clinched a long-term deal with Novo Nordisk to jointly market the latter’s blockbuster weight loss drug, Wegovy.

With the partnership, the company said that Americans can now access NovoCare Pharmacy directly through its platform, with a bundled offering of all dose strengths of Wegovy and a Hims & Hers membership, including access to 24/7 care, ongoing clinical support, and nutrition guidance, among others.

It can be learned that HIMS used to make a compounded knock-off version of the treatment that helped propel its sales over the past few years. It was later discontinued after the Food and Drug Administration announced that Novo Nordisk had already produced a sufficient supply of the treatment.